Asimov is pioneering the integration of synthetic biology and computational tools to develop an end-to-end platform for advanced genetic engineering. Concentrating on the design and production of sophisticated therapies, Asimov offers a comprehensive solution encompassing biologics, viral vectors, and programmable medicines. Their platform is engineered to equip businesses with the tools and insights required to harness the potential of living cells for therapeutic purposes.